𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis C genotypes in liver transplant recipients: Distribution and 1-year follow-up

✍ Scribed by Zein, Nizar N. ;Rakela, Jorge ;Poterucha, John J. ;Steers, Jeffery L. ;Wiesner, Russell H. ;Persing, David H.


Publisher
Wiley (John Wiley & Sons)
Year
1995
Tongue
English
Weight
355 KB
Volume
1
Category
Article
ISSN
1074-3022

No coin nor oath required. For personal study only.

✦ Synopsis


Chronic hepatitis C infection (CH-C) accounts for a significant number of patients undergoing orthotopic liver transplantation (OLT). Recently, hepatitis C virus (HCV) genotype-dependent differences in disease outcome and therapeutic responses have been suggested. The objectives of our study were to determine (1) the recurrence of HCV infection after OLT; (2) distribution of HCV genotypes in patients with CH-C who required liver transplantation compared with those who did not; and (3) the 1-year transplantation outcome in patients infected with different hepatitis C genotypes. RNA was extracted from sera of 20 patients who underwent OLT for end-stage liver disease secondary to CH-C (group I) and 52 patients with CH-C who did not require OLT (group 11). For viral RNA detection, reverse transcriptase and polymerase chain reaction (RT/PCR) of 5'UT region was performed on all OLT patients both before and after OLT. For genotyping, RT-PCR of the NS 5 region was performed, followed by automated sequencing of the amplification products. Nineteen OLT patients had viral RNA detected by PCR nfection with the hepatitis C virus (HCV) has I been identified as the major cause of posttransfusion non-A, non-B hepatitis. 1 ~2 Chronic liver disease occurs in about 50% of patients with acute HCV infection, and cirrhosis develops in 20% of these ~a t i e n t s . ~ Therefore, chronic hepatitis C infection (CH-C) accounts for a significant number of patients with end-stage liver disease undergoing orthotopic liver transplantation (OLT). Recently, it has been discovered that HCV is not a single virus but a family of related viral genotypes based on nucleotide sequence analysis of several viral genetic determinant^.^


πŸ“œ SIMILAR VOLUMES


Follow-up of Chinese liver transplant re
✍ Sheung Tat Fan; Haibo Wang; Banny K. Lam πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 302 KB πŸ‘ 1 views

The outcome of liver transplantation in China remains speculative. From 1998 to 2007, 177 adult Hong Kong patients underwent liver transplantation in China and were subsequently followed up at Queen Mary Hospital, Hong Kong. One hundred six (59.9%) patients had hepatocellular carcinoma (HCC). The gr

Unexpected distribution of hepatitis C v
✍ Renata M. Perez; Maria Lucia G. Ferraz; Mauro S. Figueiredo; Denilson Contado; S πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 72 KB

## Abstract The distribution of hepatitis C virus (HCV) genotypes in patients on hemodialysis and in kidney transplant recipients was compared with that observed in a control group composed of HCV‐infected individuals from the general population. A total of 340 patients were included in the study:

Treating hepatitis C infection in liver
✍ Norah A. Terrault; Marina Berenguer πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 192 KB πŸ‘ 1 views

Chronic infection with hepatitis C virus (HCV) is a growing problem worldwide, with up to 300 million individuals infected, and those with chronic infection are at risk for cirrhosis and hepatocellular carcinoma. HCV infection is the most common indication for liver transplantation in the United Sta

Treatment of hepatitis C in liver transp
✍ Fredric D. Gordon; Paul Kwo; Hugo E. Vargas πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 182 KB πŸ‘ 1 views

Recurrent hepatitis C after liver transplantation is a universal phenomenon. Graft reinfection occurs rapidly; once it is established, allograft cirrhosis and decompensation rapidly ensue in many patients. Treatment with pegylated interferon plus ribavirin is the standard of care among nontransplant

Alemtuzumab induction in non-hepatitis C
✍ Josh Levitsky; Kavitha Thudi; Michael G. Ison; Edward Wang; Michael Abecassis πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 220 KB πŸ‘ 1 views

Limited data exist for the use of alemtuzumab (AL) induction in liver transplantation (LT) recipients. We compared the outcomes of hepatitis C virus-negative LT recipients who received AL induction followed by tacrolimus and mycophenolate mofetil without steroids to cohort who received no AL inducti

One-year protocol liver biopsy can strat
✍ Roberto J. Firpi; Manal F. Abdelmalek; Consuelo Soldevila-Pico; Roniel Cabrera; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 224 KB πŸ‘ 1 views

Determinants of progression to cirrhosis in hepatitis C virus (HCV) infection have been well described in the immunocompetent population but remain poorly defined in liver transplant (LT) recipients. This cohort study determines the factors contributing to the development of fibrosis and its rate of